Medacta receives FDA clearance for augmented reality-based TKA platform
Medacta Group SA has received FDA clearance for its NextAR augmented reality-based platform technology, which is designed for total knee arthroplasty, according to a press release.
The platform, engineered with artificial intelligence and machine learning, is the first FDA-cleared augmented reality technology to enhance visualization during real-time TKA procedures.
“Patients and surgeons are attracted by improved outcomes and innovation, the NextAR platform is one Medacta answer to the current race in orthopedic technology and I am very excited about this milestone achievement, Francesco Siccardi, CEO of Medacta, said in the release. “Requiring a very limited investment in capital equipment, the NextAR platform perfectly represents Medacta’s commitment to develop solutions that are able to improve patient outcomes and health care system sustainability,” he said.